PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q95661

Kazuyuki OHMOTO, et al.

Appln. No.: Based on PCT/JP04/019753

Confirmation No.: Unknown Group Art Unit: Unknown

Filed: June 26, 2006 Examiner: Unknown

For: PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DISEASE IN WHICH

MITOCHONDRIAL BENZODIAZEPHINE RECEPTOR PARTICIPATES

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

A copy of an International Search Report in a counterpart application is submitted herewith. The USPTO should receive copies of the references cited in the International Search Report from the International Bureau. Applicant will furnish any missing references upon request.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

10/584280 AP3Rec d PCT/PTO 26 JUN 2000

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: Based on PCT/JP04/019753

Attorney Docket No: Q95661

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

foreign language documents, Applicant encloses herewith a copy of a Communication from a

foreign patent office in a counterpart application citing such documents (International Search

Report for PCT/JP04/019753 dated March 22, 2005), together with an English-language version

(if not already included) of at least that portion of the Communication indicating the degree of

relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

k Boland istration No. 32,197

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: June 26, 2006

2

10/584280

AB3 Rec'd PCT/PTO 26 JUNY PRESD PTO/SB/08 A & B (08-03)

Complete if Known

Unknown

June 26, 2006

Based on PCT/JP04/019753

Substitute for Form 1449 A & B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

<u>317</u>	TENIENI DI A	MILICA	4111	First Named Inventor	Kazuyuki OHMOTO Unknown	
(use as many sheets as	s necessar	v)	Art Unit		
				Examiner Name	Unknown	
Sheet	1	of	1	Attorney Docket Number	Q95661	

Application Number

Filing Date

Confirmation Number

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number		- Publication Date		
		Number	Kind Code ² (if known) B1	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document Genzyme Corp.	
	,	US 6,410,533		06-25-2002		
,		ÚS				
, ,	-	US				
		US	,			
		US	'			
		US	-			
· ·		US			. , , ,	
		ÜŠ			, , , , , , , , , , , , , , , , , , , ,	
	7	US	,	,		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date	Name of Patentee or	
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
'		WO	2003/030937	A1	04-17-2003	ONO PHARMACEUTICAL CO., LTD.	
. \		wo '	2003/068753	Aİ	08-21-2003	ONO PHARMACEUTICAL CO., LTD.	
		JP	11-171865	Α	06-29-1999	Yoshitomi Pharmaceutical Industries Ltd.	ļ.
		JР	2002-510683	A	04-09-2002	AUSTALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANIZATION	
		JP	10-130150	A	05-19-1998	Dainippon Pharmaceutical Co., Ltd.	
	,						
	· · · · · · · · · · · · · · · · · · ·						
		<u> </u>					

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published. International Search Report for PCT/JP04/019753 dated March 22, 2005				
	,					
	7 .:					

	, , , , , , , , , , , , , , , , , , , ,		
	i e e e e e e e e e e e e e e e e e e e		
D 1 C1 1		15.6	
Examiner Signature		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.